← Back to Search

Anti-metabolites

SBRT with concurrent chemotherapy for Pancreatic Cancer

Phase 2
Recruiting
Led By Benhua Xu, PHD
Research Sponsored by Fujian Medical University Union Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to 2 years after the end of treatment
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

Exploratory assessment of the efficacy and safety of gemcitabine-albumin-based paclitaxel chemotherapy combined with SBRT in the treatment of newly diagnosed borderline resectable and locally advanced unresectable pancreatic cancer patients with sequential investigator selection (IC).

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to 2 years after the end of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to 2 years after the end of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Kaplan-Meier Estimate of Progression-Free Survival (PFS)
Secondary study objectives
Disease Control Rate (DCR)
Kaplan-Meier Estimates for Overall Survival (OS)
Kaplan-Meier Estimates for Time to Treatment Failure (TTF)
+2 more

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SBRT with concurrent chemotherapyExperimental Treatment2 Interventions
SBRT with nab-Paclitaxel plus Gemcitabine (nab-P+Gem) chemotherapy

Find a Location

Who is running the clinical trial?

Fujian Medical University Union HospitalLead Sponsor
157 Previous Clinical Trials
373,019 Total Patients Enrolled
Benhua Xu, PHDPrincipal InvestigatorFujian Medical University Union Hospital
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top